Evidence map›Paper›PMID 24627349›Full record

Trial reportJournal of the American Society of Nephrology : JASN2014

BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Myra A Carpenter, Alin John, Matthew R Weir, Stephen R Smith, Lawrence Hunsicker, Bertram L Kasiske, John W Kusek, Andrew Bostom, Anastasia Ivanova, Andrew S Levey and 3 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00064753 (Folic Acid for Vascular Outcome Reduction In Transplantation), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00064753 phase2 / phase3completednot on this map

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran2002 to 2011Enrolled4,110ConditionsChronic Kidney Disease, Cardiovascular Disease, DeathArmsHigh Dose Multivitamin, Low Dose Multivitamin
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Antihypertensive treatment for kidney transplant recipients.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. New kidneys, old risks: cardiovascular challenges after transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Impact of Blood Pressure on Allograft Function and Survival in Kidney Transplant Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Vasopressin for Post-kidney Transplant Hypotension.Kidney international reports · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Myra A CarpenterDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina; Myra_Carpenter@unc.edu.
Alin JohnDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts;
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland;
Stephen R SmithDivision of Nephrology, Duke University, Durham, North Carolina;
Lawrence HunsickerUniversity of Iowa College of Medicine, Iowa City, Iowa;
Bertram L KasiskeHennepin County Medical Center and the University of Minnesota, Minneapolis, Minnesota;
John W KusekNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland;
Andrew BostomMemorial Hospital of Rhode Island, Pawtucket, Rhode Island;
Anastasia IvanovaDepartment of Biostatistics, University of North Carolina, Chapel Hill, North Carolina;
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts;
Scott SolomonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and.
Todd PesaventoDivision of Nephrology, Wexner Medical Center, Ohio State University, Columbus, Ohio.
Daniel E WeinerDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts;
Tufts Medical Center · USUniversity of North Carolina at Chapel Hill · USBrigham and Women's Hospital · USDuke University · USHennepin County Medical Center · USMemorial Hospital of Rhode Island · USNational Institute of Diabetes and Digestive and Kidney Diseases · USThe Ohio State University Wexner Medical Center · USUniversity of Iowa · USUniversity of Maryland, Baltimore · US

Funding

Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) TrialU01DK061700 · NIDDK · TUFTS MEDICAL CENTER · PI BOSTOM, ANDREW G. · 2001 to 2011
$29.0M
NIDDK NIH HHS U01 DK061700NIDDK NIH HHS U01-DK61700
6 · The paper itself

Abstract

The optimal BP level in kidney transplant recipients remains uncertain. This post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial cohort assessed associations of BP with a pooled cardiovascular disease (CVD) outcome and with all-cause mortality. In 3474 prevalent kidney transplant patients, mean age was 52±9 years, 63% were men, 76% were white, 20% had a history of CVD, 40% had a history of diabetes mellitus, and the median time since transplant was 4.1 years (25th to 75th percentiles, 1.7-7.4); mean systolic BP was 136±20 mmHg and mean diastolic BP was 79±12 mmHg. There were 497 CVD events and 406 deaths. After adjustment for demographic and transplant characteristics and CVD risk factors, each 20-mmHg increase in baseline systolic BP associated with a 32% increase in subsequent CVD risk (hazard ratio [HR], 1.32; 95% confidence interval [95% CI], 1.19 to 1.46) and a 13% increase in mortality risk (HR, 1.13; 95% CI, 1.01 to 1.27). Similarly, after adjustment, at diastolic BP levels<70 mmHg, each 10-mmHg decrease in diastolic BP level associated with a 31% increase in CVD risk (HR, 1.31; 95% CI, 1.06 to 1.62) and a 31% increase in mortality risk (HR, 1.31; 95% CI, 1.03 to 1.66). However, at diastolic BP levels>70 mmHg, there was no significant relationship between diastolic BP and outcomes. Higher systolic BP strongly and independently associated with increased risk of CVD and all-cause mortality, without evidence of a J shape, whereas only lower levels of diastolic BP associated with increased risk of CVD and death in this trial.

Indexed as

Kidney TransplantationBlood PressureCardiovascular DiseasesDouble-Blind MethodFemaleFolic AcidHumansHypertensionMaleMiddle AgedPostoperative ComplicationsFolic Acidblood pressurecardiovascular diseasekidney transplantationmortality

Identifiers

PMID24627349
PMCPMC4073424
OpenAlexW2140467486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.